Christopher Krawtschuk - 06 Dec 2023 Form 4 Insider Report for bluebird bio, Inc. (BLUE)

Reporting relationship: Chief Financial Officer
Issuer ticker: BLUE
Reported as of: 06 Dec 2023
Net transaction value: -$20,437
SEC form: 4
Accepted by SEC: 08 Dec 2023, 16:42:19 UTC
Prior SEC filing: 05 Dec 2022
Next SEC filing: 05 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Sydney Gaylin, Attorney-in-Fact

Key filing fact

Christopher Krawtschuk filed Form 4 for bluebird bio, Inc. (BLUE) on 08 Dec 2023.

Key facts

This page summarizes Christopher Krawtschuk's Form 4 filing for bluebird bio, Inc. (BLUE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Dec 2023, 16:42.

Change

Previous filing in this sequence was filed on 05 Dec 2022.
Current net transaction value: -$20,437.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLUE transaction

Common Stock

Sale

Transaction value: $20,437
Shares: -4,526
Change %: -9.1%
Price: $4.52
Shares after: 45,474
Date: 06 Dec 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.

Footnote F2

The range in prices for the transaction reported on this line was $4.50 to $4.55. The average weighted price was $4.5155. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.